Health Care/Hospital

Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

BEIJING, Aug. 11, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. ("Shuhai ...

2026-08-11 21:01 2581

Planet Green Enters the Fast Growing Global Lactoferrin Market, Adding Chief Scientist to Drive Innovation-Based Product Portfolio Growth

Company Gains Access to Rare and Commercially Desirable High-Quality  Lactoferrin for the Large and Rapidly Scaling Chinese Markets, Adding New Scientist to Drive New Product Development   NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Planet Green Holdings Corp. (NYSE American: PLAG) (the "Company"),...

2026-08-11 19:30 2241

NUS researchers achieve breakthrough in engineering colour-sensing yeast

In a new study, scientists engineered baker's yeast to sense and respond to different colours of light, enabling new ways to control cellular behaviour with red and blue light SINGAPORE, Aug. 11, 2026 /PRNewswire/ -- Baker's yeast is one of biotechnology's most important microorganisms. It has l...

2026-08-11 17:56 4722

Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...

2026-08-11 17:45 2607

Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery

LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation f...

2026-08-11 09:30 3574

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a clos...

2026-08-10 20:00 3854

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...

2026-08-10 12:05 2682

Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections

SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...

2026-08-10 08:00 2591

RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...

2026-08-08 15:46 4445

NutriPQQ® Publishes New PQQ Sourcing Guide for Supplement Brands and Manufacturers

The new B2B resource helps procurement, formulation, and quality teams evaluate PQQ production methods, ingredient identity, testing, stability, packaging, and supply continuity. Key Highlights * Provides a practical framework for comparing PQQ suppliers beyond quoted price and assay percenta...

2026-08-07 23:00 1752

STARCARES Revamps Basketball Court at the University of Lagos for Future Healthcare Professionals

The revitalised basketball court gives approximately 2,000 future healthcare professionals a dedicated space to recharge, connect, and build community activities beyond their academic training LAGOS, Nigeria, Aug. 7, 2026 /PRNewswire/ -- STARCARES, the community impact initiative of STARTRADER, ...

2026-08-07 16:30 3776

Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China

NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...

2026-08-07 14:44 4041

Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...

2026-08-06 19:30 2385

Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment ...

2026-08-06 16:10 3107

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2026-08-06 08:00 4463

Nearly 3 in 10 Veterinarians at Japan's Larger Companion-Animal Hospitals Say Their Current Pace Is Unsustainable, Zpeer Survey Finds

TOKYO, August 5, 2026 /PRNewswire/ -- Zpeer Inc., operator of Vetpeer — Japan's largest online community for veterinary professionals, reaching approximately 80% of the country's small-animal veterinarians —today released the results of a survey of 314 companion-animal veterinarians on their work...

2026-08-05 21:00 3054

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA).This milestone qualifies Porton Advanced to undertak...

2026-08-05 20:00 2146

Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product

* Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 * Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments * Addition...

2026-08-05 20:00 2529

INTCO Medical Recognized in S&P Global Sustainability Yearbook (China Edition) 2025 for ESG Progress

ZIBO, China, Aug. 5, 2026 /PRNewswire/ -- INTCO Medical  ("the Company"), a leading global manufacturer of disposable gloves, has been included in S&P Global's Sustainability Yearbook (China Edition) 2025 and recognized as an Industry Mover for its ESG progress, re...

2026-08-05 17:27 2975

JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results

CHANGZHOU, China, Aug. 4, 2026 /PRNewswire/ -- JIN MEDICAL INTERNATIONAL LTD. (Nasdaq: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, today announced its unaudit...

2026-08-05 04:30 4770
1 ... 6789101112 ... 321

Week's Top Stories